$LXRX News
Last published 13h ago
- 13h agoLXRXLexicon Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in LondonGlobeNewswireTHE WOODLANDS, Texas, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a leading cardiometabolic biopharmaceutical company, today announced that Company management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on Wednesday, November 18, 2026, at 8:00 a.m. GMT in London.
- 2d agoLXRXNew Data at 2026 American Heart Association Scientific Sessions Highlight Cardiovascular Effects of Sotagliflozin on Thrombus Formation and in Hypertrophic CardiomyopathyGlobeNewswire-- In a randomized crossover study, sotagliflozin significantly reduced ex vivo thrombus formation from baseline under both arterial and venous flow conditions -- -- Study in living human heart tissue indicate
- 6d agoLXRXLEXICON PHARMACEUTICALS, INC. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 6d agoLXRXLexicon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Clinical UpdatesGlobeNewswirePhase 3 SONATA-HCM study substantially overenrolled; top-line data expected Q1 2027 Positive STENO1 safety data strengthens benefit-risk profile for ZYNQUISTA® NDA resubmission Phase 1 clinical development of LX9851
- 1w agoLXRXLexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026GlobeNewswireTHE WOODLANDS, Texas, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), a leading cardiometabolic biopharmaceutical company, today announced the Company will release its third quarter
- 2w agoLXRXLexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic CardiomyopathyGlobeNewswire-- Patient demographics consistent with prior studies of other agents in HCM and reflect real-world clinical practice -- -- Mean baseline KCCQ-CSS of 59 shows considerable symptom burden at study entry –
- 3w agoLXRXLexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin’s Biological Effects in Cardiovascular DiseaseGlobeNewswire-- Preclinical study demonstrates positive effects of sotagliflozin on cardiac function and structure in hypertrophic cardiomyopathy -- -- Second preclinical study shows inhibitory effects of sotagliflozin on platelet
- 2mo agoLXRXLexicon Pharmaceuticals to Participate at Three Upcoming Investor ConferencesGlobeNewswireTHE WOODLANDS, Texas, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that company management will present at three upcoming investor conferences taking place in New
- 2mo agoLXRXLexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart FailureGlobeNewswireTHE WOODLANDS, Texas, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced results from a post hoc analysis of the Phase 3 SOLOIST-WHF trial evaluating the efficacy and safety
- 2mo agoLXRXLexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851GlobeNewswireLX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders Lexicon is eligible to receive up to $1 billion in total upfront
- 3mo agoLXRXLexicon Pharmaceuticals 2nd Quarter 2026 Results Conference Call - LEXICON PHARMACEUTICALS INCEarnings Call TranscriptsWelcome to the Lexicon Pharmaceuticals Second Quarter 2026 Financial Results Conference Call. At this time, all participants are in listen-only mode. Following management's prepared remarks, we will hold a brief question
- 3mo agoLXRXLexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical UpdatesGlobeNewswireEnrollment complete in Phase 3 SONATA-HCM study; top-line data expected Q1 2027 NDA resubmission activities for ZYNQUISTA® in type 1 diabetes nearing completion Phase 1 clinical development of LX9851 ongoing by Novo
- 3mo agoLXRXApproval of Inpefa, Nda #216203 (Labeling)FDA Approved DrugsApproval Date: 08/06/2026; Drug Name: Inpefa, Nda #216203; Active Ingredients: SOTAGLIFLOZIN; Company: Lexicon Pharms Inc; Submission Status: Approval; Submission Classification: Labeling; Application Number: 216203
- 3mo agoLXRXLexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026GlobeNewswireTHE WOODLANDS, Texas, July 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the Company will release its second quarter 2026 financial results on Thursday, August 6, 2026, prior
- 3mo agoLXRXLexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)GlobeNewswireStudy substantially exceeded enrollment target of 500 patients Topline results anticipated in Q1 2027 THE WOODLANDS, Texas, July 27, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today
- 5mo agoLXRXLexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific SessionsGlobeNewswireTHE WOODLANDS, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that it will present data from clinical studies of sotagliflozin in Type 1 diabetes (T1D) and
- 5mo agoLXRXLexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare ConferenceGlobeNewswireTHE WOODLANDS, Texas, May 28, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Company management will participate in a fireside chat at the 2026 Jefferies Global Healthcare
- 6mo agoLXRXLexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor ConferenceGlobeNewswireTHE WOODLANDS, Texas, May 12, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Company management will participate in a fireside chat at the 4th Annual H.C. Wainwright
- 6mo agoLXRXLexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical UpdatesGlobeNewswireSONATA-HCM anticipated to be fully enrolled mid-2026 Resubmission of NDA for ZYNQUISTA® in type 1 diabetes anticipated mid-2026 with potential for approval this year Clinical development of LX9851 initiated by
- 6mo agoHTGCLXRXLexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules CapitalGlobeNewswireTHE WOODLANDS, Texas, May 04, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced today that it has entered into a loan facility with Hercules Capital, Inc. (NYSE:HTGC) that provides up to
- 6mo agoLXRXLexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026GlobeNewswireTHE WOODLANDS, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the Company will release its first quarter 2026 financial results on Thursday, May 7, 2026, prior to
- 6mo agoLXRXLexicon to Present Data at the American Academy of Neurology (AAN) Annual MeetingGlobeNewswireOral presentation highlights additional data from PROGRESS Phase 2b study of pilavapadin supporting selection of 10mg as optimal dose for Phase 3 development in DPNP New data on spasticity further validates the
- 7mo agoLXRXLexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & ExpoGlobeNewswireTHE WOODLANDS, Texas, March 24, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced three presentations of sotagliflozin clinical data during the American College of Cardiology (ACC)
- 7mo agoLXRXLexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851GlobeNewswireLX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders Lexicon has earned a second of three potential $10 million
- 8mo agoLXRXLexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical UpdatesGlobeNewswirePivotal sotagliflozin milestones on schedule including resubmission of NDA in T1D and enrollment of SONATA study for HCM Positive End-of-Phase 2 meeting with FDA for pilavapadin confirms Phase 3 readiness and supports
- 8mo agoMLYSPROKIRONREGN+5Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsightPR NewswireRecently published Chronic Kidney Disease Market Insights report includes a comprehensive understanding of current treatment practices, chronic...
- 8mo agoLXRXLexicon Pharmaceuticals to Participate in Three Upcoming March Investor ConferencesGlobeNewswireTHE WOODLANDS, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Company management will participate in an upcoming fireside chat at the 2026 Leerink Partners
- 8mo agoLXRXLexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026GlobeNewswireTHE WOODLANDS, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the Company will release its fourth quarter 2025 financial results on Thursday, March 5, 2026, prior
- 9mo agoLXRXLexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private PlacementGlobeNewswireTHE WOODLANDS, Texas, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) ("Lexicon") today announced the closing of its previously announced underwritten public offering of 32,000,000 shares
- 9mo agoLXRXLexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private PlacementGlobeNewswireTHE WOODLANDS, Texas, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) ("Lexicon") today announced the pricing of its previously announced underwritten public offering of 32,000,000 shares
- 9mo agoLXRXLexicon Announces Proposed Public Offering of Common StockGlobeNewswireTHE WOODLANDS, Texas, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) ("Lexicon") today announced that it has commenced an underwritten public offering to offer and sell, subject to market
- 9mo agoLXRXLexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th AnniversaryGlobeNewswireTHE WOODLANDS, Texas, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the Company will ring the Nasdaq Stock Market Closing Bell on Tuesday, January 27, 2026. The event
- 9mo agoLXRXLexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic PainGlobeNewswireTHE WOODLANDS, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the successful completion of the End-of-Phase 2 (EOP2) Meeting with the U.S. Food and Drug
- 9mo agoVTRSLXRXViatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart FailurePR NewswireViatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced the launch of Inpefa® (sotagliflozin) in the United Arab Emirates (UAE),...
- 10mo agoLXRXLexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireSONATA-HCM on track for enrollment completion in 2026 and topline data in 2027 $10 million milestone payment triggered from licensing agreement with Novo Nordisk for LX9851 Zynquista on track for NDA
- 10mo agoLXRXLexicon Pharmaceuticals Publishes "Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain"GlobeNewswire-White Paper based on October 2025 Roundtable of diverse stakeholders focused on accelerating innovation and expanding access to novel non-opioid therapies- -Need for swift action by policymakers to support millions of
- 10mo agoLXRXLexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireTHE WOODLANDS, Texas, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Company management will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday,
- 11mo agoLXRXLexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851GlobeNewswireTHE WOODLANDS, Texas, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the publication of preclinical data validating Acyl-CoA Synthetase 5 (ACSL5) as a target for obesity
- 11mo agoLXRXClinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists ForumGlobeNewswireTHE WOODLANDS, Texas, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced clinical data on adipose tissue distribution in non-diabetic patients treated with sotagliflozin will be
- 11mo agoLXRXLexicon Pharmaceuticals to Participate in Two Upcoming December Investor ConferencesGlobeNewswireTHE WOODLANDS, Texas, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Company management will participate in a fireside chat at the Piper Sandler 37th Annual
- 1y agoLXRXLexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare ConferenceGlobeNewswireTHE WOODLANDS, Texas, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Company management will participate in a fireside chat at the Jefferies 2025 London Healthcare
- 1y agoLXRXClinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025GlobeNewswireTHE WOODLANDS, Texas, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that new sotagliflozin clinical data was presented at the AHA Annual Scientific Sessions 2025. The
- 1y agoLXRXLexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D UpdatesGlobeNewswireFDA End-of-Phase 2 meeting for pilavapadin in DPNP to be held by year-end All IND-enabling studies of LX9851 for obesity completed and submitted to licensee Novo Nordisk Site initiation for SONATA-HCM Phase 3 study
- 1y agoLXRXData Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association's Sessions 2025 in New OrleansGlobeNewswireTHE WOODLANDS, Texas, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that data from three studies of sotagliflozin will be presented during upcoming medical meetings. Two
- 1y agoLXRXLexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025GlobeNewswireTHE WOODLANDS, Texas, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the Company will release its third quarter 2025 financial results on Thursday, November 6, 2025, prior
- 1y agoLXRXLexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics SummitGlobeNewswire– Results support advancement of 10 mg dose into Phase 3 development – – End-of-Phase 2 meeting request accepted by U.S. FDA; partnership discussions progressing – THE WOODLANDS, Texas, Oct. 14, 2025 (GLOBE NEWSWIRE)
- 1y agoLXRXLexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic PainGlobeNewswireTHE WOODLANDS, Texas, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Yesterday, Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) hosted and participated in a roundtable discussion with experts to explore how to enhance current and
- 1y agoLXRXLexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 DiabetesGlobeNewswireData obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete response letter Company seeks alignment on reasonable path forward for
- 1y agoLXRXPilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual MeetingsGlobeNewswireTHE WOODLANDS, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the presentation of clinical data from the company's Phase 2b PROGRESS study for its investigational,
- 1y agoLXRXLexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical MeetingsGlobeNewswirePresentations collectively highlight pilavapadin's potential to improve pain management care for patients with diabetic peripheral neuropathic pain (DPNP) Breadth of the data across Phase 2 program to be discussed at